Navigation Links
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
Date:8/3/2009

RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 is the first orally-administered irreversible dual inhibitor of EGFR and HER2,(1) to reach Phase III development in NSCLC.(2)

The LUX-Lung 3 trial will compare the efficacy and safety of the single-agent BIBW 2992 to that of standard chemotherapy (cisplatin/pemetrexed) as a potential first-line treatment for NSCLC patients with EGFR mutations.(3) Boehringer Ingelheim's LUX-Lung trial program currently includes two Phase III trials assessing the efficacy and safety of BIBW 2992 in various NSCLC patient populations across the globe.

"The Boehringer Ingelheim LUX-Lung 3 trial studying BIBW 2992 in patients with EGFR mutations will be important as we continue to work towards providing personalized medicine for patients with lung cancer," said James Yang, MD, PhD, professor at the Graduate Institute of Clinical Medicine and the Graduate Institute of Clinical Pharmacy at the College of Medicine at the National Taiwan University (NTU). "BIBW 2992 is an irreversible tyrosine kinase inhibitor(1) whose clinical benefit we are hoping to confirm in the first-line setting for patients with EGFR mutations."

This milestone coincides with the oral presentations of new data at WCLC suggesting the compound's potential:

  • Preliminary data from the Phase II LUX-Lung 2 trial of NSCLC patients with an EGFR mutation show a response rate of nearly two-thirds (63%) and a disease control rate of 97% in 38 evaluable first-line patients.(4) The most commonly (greater than 5%) observe
    '/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
2. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
3. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
4. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
5. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
6. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
7. Emdeon Inc. Commences U.S. Initial Public Offering of Class A Common Stock
8. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
9. HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Cogdell Spencer Announces Commencement of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
(Date:10/20/2014)... It’s hard to imagine what it’s like ... children around the world, it’s a reality. And while new ... are forced to walk barefoot on rocky terrain or sewage-lined ... with their friends. , Buckner International's Shoes for ... in October to encourage support for Air1 and while ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest ... and HostMonster are the best VPS hosting suppliers ... is the method of partitioning a physical server ... the appearance and capabilities of running on someone’s ... pays close attention to VPS products and related ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... Professor of Psychology, Annenberg Professor of Natural ... Neuroscience, University of Pennsylvania , WHAT: Dr. Farah ... of the symposium Poverty and Brain Development: ... 2008 American Association for the Advancement of ...
... differ on what answers the research offers , , TUESDAY, ... try to answer one of the most pressing questions ... applied to keep open the partially collapsed lungs of ... respiratory distress syndrome? , Unfortunately, that question has not ...
... Phileas Fogg,s 80-Day Around the World Race Updated for ... Oscar Viewing Party February 24, NEW YORK, Feb. ... legends were launched: the Academy Awards and The Leading,Hotels ... milestone, Leading,Hotels has drawn on all the adventure, romance ...
... Northwestern Memorial,HealthCare, corporate parent of Northwestern Memorial ... new members to the Northwestern,Memorial Foundation,s Boards of ... currently serves as president of the Friends of ... Northwestern Memorial Hospital,s,Campaign Steering Committee. Gordon is chairman ...
... Feb. 12 Thomson Healthcare, the,leading provider of ... their efforts to improve clinical and business,performance, announced ... as the Category Leader for Mobile Data Systems ... report released in December 2007., For the ...
... Development Event ... Personal Care Industry, NEW YORK, Feb. 12 Jill ... & Fragrances Business Division,for CMPi, the producers of the HBA ... sales, marketing, and operations of the annual,HBA Global Expo and ...
Cached Medicine News:Health News: Respiratory Distress Treatment Studies Conflict 2Health News: Respiratory Distress Treatment Studies Conflict 3Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 2Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 3Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 4Health News:The Leading Hotels of the World Recreates Film Fantasy in Uber-Luxury Trip: Around The World in 80 Ways 5Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:Thomson Healthcare's Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year 2Health News:Thomson Healthcare's Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year 3Health News:Jill Birkett Appointed Event Director for HBA Global Expo 2Health News:Jill Birkett Appointed Event Director for HBA Global Expo 3
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
(Date:10/17/2014)... Texas , Oct. 17, 2014  Hanger, Inc. ... plans to report its results of operations for the ... 2014 after the market closes.  A conference call to ... a.m., ET, on Friday, November 7, 2014. Those wishing ... available until Friday, November 14, 2014 by dialing 1-855-859-2056 ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Calif., Dec. 9, 2010 Ambry Genetics, a global ... sciences industries, announced today that it has officially launched ... Genetics has been an early adapter of Illumina sequencing ... Certified Service Provider. (Logo:   http://photos.prnewswire.com/prnh/20090428/LA06744LOGO ...
... 9, 2010 A new study shows that ... hormonal therapy tamoxifen in patients with hormone-receptor positive/human ... cancer who have been previously treated with an ... tamoxifen alone. These results were presented today at ...
Cached Medicine Technology:Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 3Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 4Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 5Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 6Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 7Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 8Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 9Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 10Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 11
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Male Body Shaper, Mid-thigh...
Medicine Products: